Array Biopharma, Inc. (ARRY) Reports Q2 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.29 -3.52%
Revenue Growth %: -18.0%
Financial Fact:
Interest expense: -2.98M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: -18.0%
Financial Fact:
Interest expense: -2.98M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at BMO Capital
- American Airlines (AAL) Tops Q3 EPS by 5c, Offers Guidance
- Ryder System (R) Tops Q3 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
